Tanvex BioPharma
Biosimilar developer, Taiwan. 1 development product across 1 molecule: filgrastim.
First approval in the Atlas: Oct 2021, Nypozi, filgrastim (HC)
FDAproducts approved1
EMAproducts approved0
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Filgrastim | Nypozi TX01 | Jun 2024 | · | · | Oct 2021 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- HCOct 2021Nypozi, filgrastim
- FDAJun 2024Nypozi, filgrastim
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.